Alkermes
NEWS
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
Shares of Alkermes plc are down about 19 percent in premarket trading after the U.S. FDA rejected the company’s NDA for its major depressive disorder treatment ALKS-5461.
With no end to the national opioid crisis in sight, the U.S. Department of Justice announced a plan to form a task force that will target opioid manufacturers and distributors.
After a huge dry spell in M&A, 2018 is shaping up to be a great year for deal making.
Three biotech stocks gained over 25 percent last week.
Here are three biopharma stocks worth keeping an eye on.
JOBS
IN THE PRESS